ArticleCancer medicine2026
Real-World Efficacy of Nab-Paclitaxel Plus Capecitabine and a PD-1 Inhibitor in Metastatic or Locally Advanced Esophageal Cancer.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundOver half of esophageal cancer (EC) cases occur in China, where paclitaxel and platinum agents have become the preferred chemotherapeutic regimen for EC patients. However, there is a clinical need for a non-platinum-based therapeutic option.
methodsCases were collected from Sun Yat-sen University Cancer Center between January 2019 and November 2023. Patients with metastatic or locally advanced EC received 4-6 cycles of chemo-immunotherapy, including nab-paclitaxel, capecitabine, and a programmed death receptor 1 (PD-1) inhibitor, with or without subsequent surgery, radiotherapy, or maintenance therapy. The objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), pathological complete response (pCR), complete (R0) resection rate, and major pathologic response (MPR) were assessed.
resultsAmong the 72 patients retrospectively analyzed, the median PFS was 24.7 months (95% confidence interval: 7.0-42.3 months). 75% of patients were regarded as responders, with an ORR of 66.7% in 42 patients with measurable lesions. The 6-month, 1-year, and 2-year PFS rates (DCRs) were 100%, 96.2%, and 67.9%, respectively. In total, 9 patients underwent surgery, and 29 patients received radiotherapy following the regimen. The R0 resection rate was 77.8%, while both pCR and MPR were 66.7%. The most common adverse events were myelosuppression (27.8%) and liver dysfunction (25.0%).
conclusionOur study demonstrated that the combination of nab-paclitaxel, capecitabine, and a PD-1 inhibitor was an effective and tolerable strategy for EC patients and a promising first-line or neoadjuvant treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.